Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving ...
– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants evaluable at ...
I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...
Evans Buntley is one of 349 people who has received $500 per month from the city of Rochester as part of the city's Guaranteed Basic Income year long pilot program. Buntley, who has a full-time job ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results